Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • W. Soliman
  • M. Vinten
  • B. Sander
  • K.A.E.N. Soliman
  • S. Yehya
  • M.S.A. Rahman
  • Larsen, Michael
Purpose: To assess the effect of intravitreal bevacizumab on diabetic macular oedema (DMO) and retinal vessel calibres. Methods: We performed a consecutive case series study in which 10 consecutive eyes with diffuse DMO, two of which had not previously been treated, received an intravitreal injection of bevacizumab 1 mg, which was followed by two more injections at 6-week intervals. Fundus photography and optical coherence tomography (OCT) were carried out at baseline immediately before injection and at 1, 2.5 and 4 months after the first injection. Outcome measures were best corrected visual acuity (BCVA) in Early Treatment Diabetic Retinopathy Study letters, macular volume, foveal subfield thickness and vessel diameter measurement. Results: Intravitreal administration of bevacizumab was followed by a mean increase in BCVA of 7.3 +/- 17 (mean +/- standard deviation) letters between baseline and month 4, which was 1 month after the last injection (p < 0.0001). This was accompanied by a reduction in mean macular volume from 9.90 +/- 1.9 mm(3) to 8.96 +/- 2.4 mm(3) (p = 0.002) and in foveal subfield thickness from 447 +/- 117 mu m to 388 +/- 117 mu m (p = 0.03). Two eyes with early proliferative diabetic retinopathy lost all signs of proliferation without any evidence of fibrosis. Although there was a trend towards vasoconstriction, the changes in vessel diameters (arteries and veins) after 4 months of intravitreal Avastin injection were not statistically significant (p = 0.9 and p = 0.17, respectively). Foveal thickness in non-injected fellow eyes with DMO changed from 428 +/- 153 mu m at baseline to 383 +/- 151 mu m at 4 months (p = 0.1), which did not reach statistical significance. Conclusions: Intravitreal bevacizumab 1 mg every 6 weeks was followed by a moderate reduction in DMO without normalization of foveal and macular thickness. Our observations suggest that a larger study where patients are examined sooner after injection is needed to elucidate the potential relationship between changes in retinal vessel diameters and thickness changes in DMO
Udgivelsesdato: 2008/6
OriginalsprogEngelsk
TidsskriftActa Ophthalmologica Scandinavica
Vol/bind86
Udgave nummer4
Sider (fra-til)365-371
Antal sider6
ISSN1395-3907
StatusUdgivet - 2008

Bibliografisk note

Times Cited: 0ArticleEnglishSoliman, WUniv Copenhagen, Glostrup Hosp, Dept Ophthalmol, DK-2600 Glostrup, DenmarkCited References Count: 22309YTBLACKWELL PUBLISHING9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLANDOXFORD

ID: 13860736